Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Lucia Musacchio"'
Autor:
Floriana Camarda, Mariachiara Paderno, Maria Chiara Cannizzaro, Camilla Nero, Ilaria Sabatucci, Giovanni Fucà, Lucia Musacchio, Vanda Salutari, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Cervical cancer (CC) is still characterized by a poor prognosis despite the progress made in its treatment in recent years. Although immunotherapy has improved outcomes for advanced/recurrent disease, there is a significant gap in addressing patients
Externí odkaz:
https://doaj.org/article/a32e045a7b8b48adb04dd3a85af00de2
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which l
Externí odkaz:
https://doaj.org/article/de90d78883344f6981f9661c5febad53
Autor:
Lucia Musacchio, Carlo Maria Cicala, Vanda Salutari, Floriana Camarda, Maria Vittoria Carbone, Viola Ghizzoni, Elena Giudice, Camilla Nero, Maria Teresa Perri, Caterina Ricci, Francesca Tronconi, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Lurbinectedin is an antitumor agent belonging to the natural marine-based tetrahydroisoquinoline family which has shown very promising clinical activity with a favorable safety profile in many types of cancer. Preclinical evidence showed that lurbine
Externí odkaz:
https://doaj.org/article/65a510a19fcf43339f3b7c709435c5e8
Autor:
Giuseppe Caruso, Lucia Musacchio, Giusi Santangelo, Innocenza Palaia, Federica Tomao, Violante Di Donato, Giorgia Perniola, Vanda Salutari, Pierluigi Benedetti Panici
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 3, Pp 1317-1324 (2020)
Although ovarian cancer often presents as a widespread disease, metastases to the breast and/or axillary lymph nodes are a very rare event, accounting for only 0.03–0.6% of all breast cancers. Its early recognition and accurate distinction from pri
Externí odkaz:
https://doaj.org/article/ff0592aa0fc449038f51c2eef3ce6ee0
Autor:
Elena Giudice, Marica Gentile, Vanda Salutari, Caterina Ricci, Lucia Musacchio, Maria Vittoria Carbone, Viola Ghizzoni, Floriana Camarda, Francesca Tronconi, Camilla Nero, Francesca Ciccarone, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Cancers, Vol 14, Iss 6, p 1420 (2022)
PolyADP-ribose polymerase (PARP) inhibitors (PARPis) represent the first clinically approved drugs able to provoke “synthetic lethality” in patients with homologous recombination-deficient (HRD) tumors. Four PARPis have just received approval for
Externí odkaz:
https://doaj.org/article/b1c2bae9fba647ccb0f1d3152b0b72ce
Autor:
Alessandra Giustozzi, Vanda Salutari, Elena Giudice, Lucia Musacchio, Caterina Ricci, Chiara Landolfo, Maria Teresa Perri, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Biology, Vol 10, Iss 9, p 845 (2021)
Endometrial carcinoma is the most frequent cancer of the reproductive female organs. Most endometrial cancers are diagnosed at early stage (75%). Treatment options depend on pathogenetic, histopathologic and clinical characteristic at the diagnosis.
Externí odkaz:
https://doaj.org/article/f61a24f0a63c461599492a83a1a92179
Autor:
Lucia Musacchio, Serena Maria Boccia, Giuseppe Caruso, Giusi Santangelo, Margherita Fischetti, Federica Tomao, Giorgia Perniola, Innocenza Palaia, Ludovico Muzii, Sandro Pignata, Pierluigi Benedetti Panici, Violante Di Donato
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 6, p 1721 (2020)
Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the
Externí odkaz:
https://doaj.org/article/b98dc20b109a4c19916fb53bc55dc051
Autor:
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone, Valentina Accinno, Chiara Altavilla, Giovanna Antonelli, Grazia Artioli, Francesco Avola, Bonifacio Barbara, Valentina Barbato, Michele Bartoletti, Simona Bevilacqua, Roberto Bordonaro, Oriana Borghese, Gaetano Buonfanti, Floriana Camarda, Giuliana Canzanella, Vittoria Carbone, Maria Rita Carbone, Giulia Carlo Stella, Chiara Cassani, Fabrizio Castagna, Monica Cattaneo, Margherita Cinefra, Nicoletta Colombo, Serena Corsetti, Monia Dall'Agata, Maria D'Amico, Gennaro Daniele, Elvira De Marino, Giovanni De Matteis, Sabino De Placido, Gabriella Del Bene, Antonia Del Giudice, Francesca Del Monte, Michele Del Sesto, Maddalena Donini, Giuliana Drudi, Gianluca Falcone, Adolfo Favaretto, Giulia Ferrera, Manuela Florio, Valeria Forestieri, Maria Stella Gallo, Ciro Gallo, Francesca Garibaldi, Fabiana Gerevini, Viola Ghizzoni, Maria Olga Giganti, Anna Gimigliano, Elena Giudice, Nicoletta Gnocchi, Adriano Gravina, Stefano Greggi, Maria Laura Iaia, Annalisa Ilardi, Gelsomina Iovine, Gabriella Ippoliti, Giulia Irollo, Ilenia Isidori, Mariateresa Lapresa, Giuseppe Lavenia, Laura Longhitano, Bortot Lucia, Gabriella Luzi, Sara Mariano, Valentina Marino, Giovanna Marrapese, Marilena Martino, Roberta Matocci, Enrica Mazzoni, Daniela Mercuri, Maria Mirto, Giovanna Mollo, Abbondanza Montinaro, Marta Moscatelli, Anna Maria Mosconi, Lucia Musacchio, Nicoletta Nanni, Pamela Natalucci, Milena Sabrina Nicoloso, Michele Orditura, Gabriella Maria Parma, Rodolfo Passalacqua, Michela Pelone, Maria Teresa Perri, Bruno Perrucci, Alessandra Piancastelli, Maria Carmela Piccirillo, Antonio Piccolo, Stefania Rapisardi, Giorgia Ravaglia, Teresa Ribecco, Caterina Ricci, Marianna Roccio, Fiorella Romano, Daniela Sambataro, Alfonso Savio, Ada Sbriglia, Cono Scaffa, Concetta Sergi, Francesca Sgandurra, Roberto Sorio, Stefano Stabile, Gianna Tabaro, Margherita Tambaro, Stefano Tamberi, Angelica Tecchiato, Angela Maria Trujillo, Eleonora Zaccarelli
Publikováno v:
The Lancet Oncology. 24:286-296
Background: Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel as first-lin
Autor:
Camilla, Di Dio, Giorgio, Bogani, Violante, Di Donato, Ilaria, Cuccu, Ludovico, Muzii, Lucia, Musacchio, Giovanni, Scambia, Domenica, Lorusso
Publikováno v:
Gynecologic Oncology. 169:27-33
Endometrial cancer is the most common gynecological disease in developed countries. Although it is considered an indolent disease, advanced and recurrent endometrial carcinomas are characterized by poor prognosis. In the metastatic setting, after the
Publikováno v:
Expert Review of Anticancer Therapy. 22:1039-1047
Endometrial cancer can be characterized by high instability of microsatellites (MSI-H), a biomarker indicative of sensibility to immune checkpoint inhibitors (ICIs). The results of the KEYNOTE-158 trial led to the approval of pembrolizumab - a monocl